Trial Profile
A Randomized, Open Label, Multicenter, Phase 2/3 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia.
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Lumiliximab (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms LUCID
- Sponsors Biogen
- 05 Oct 2021 This trial has been completed in Spain and France according to European Clinical Trials Database record. (End date: 2010-04-07)
- 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 07 Feb 2011 Trial phase changed from II to II/III as reported by Clinical Trials Registry - India.